

By: Carona

S.B. No. 730

A BILL TO BE ENTITLED

1 AN ACT

2 relating to a study concerning maximum lifetime benefit limits
3 under health benefit plan coverage applicable to
4 hemophilia-related services, supplies, pharmaceuticals, and
5 biologics.

6 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

7 SECTION 1. DEFINITION. In this Act, "department" means the
8 Texas Department of Insurance.

9 SECTION 2. STUDY. (a) The department shall conduct a study
10 of the maximum lifetime benefit limits under health benefit plan
11 coverage as those limits are applied to hemophilia-related
12 services, supplies, pharmaceuticals, and biologics.

13 (b) In conducting the study, the department shall consult
14 health benefit plan issuers, physicians, organizations
15 representing the interests of individuals with hemophilia, and the
16 office of public insurance counsel.

17 (c) The study must consider the manner in which
18 hemophilia-related services, supplies, pharmaceuticals, and
19 biologics are provided by the Texas Health Insurance Risk Pool.

20 SECTION 3. REPORT. Not later than September 1, 2008, the
21 department shall report the results of the study conducted under
22 this Act to the governor, the lieutenant governor, and the speaker
23 of the house of representatives. The report must include:

24 (1) the estimated cost for an enrollee of providing

1 coverage for hemophilia-related services, supplies,
2 pharmaceuticals, and biologics without a maximum lifetime benefit
3 limit or with an increased maximum lifetime benefit limit;

4 (2) a review of the benefits to enrollees of providing
5 coverage for hemophilia-related services, supplies,
6 pharmaceuticals, and biologics without a maximum lifetime benefit
7 limit or with an increased maximum lifetime benefit limit; and

8 (3) the recommendation of the commissioner of
9 insurance, if any, for legislation concerning the maximum lifetime
10 benefit limits under health benefit plan coverage as those limits
11 are applied to hemophilia-related services, supplies,
12 pharmaceuticals, and biologics.

13 SECTION 4. EXPIRATION. This Act expires June 1, 2009.

14 SECTION 5. EFFECTIVE DATE. This Act takes effect September
15 1, 2007.